ARKD yields 331.30% · PFE yields 6.20%● Live data
📍 ARKD pulled ahead of the other in Year 1
Combined, ARKD + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ARKD + PFE for your $10,000?
ARKD is an actively managed ETF aiming to provide a more tampered price return for shares of ARK Innovation ETF (ticker: ARKK), over a one-year period starting each January. The fund aims to cut the downside risk in half in exchange for a capped upside potential after a 5% performance hurdle is reached. ARKK holds US and foreign equities focused on disruptive innovation themes such as genomics, AI, robotics, fintech. The fund holds shares of ARKK, sells at-the-money calls against the shares, buys at-the-money puts covering 50% of the funds NAV, and buys out-of-the-money calls with any available premium in order to provide upside exposure above the 5% hurdle. All returns are before fees and expenses, which reduce overall fund returns. ARKD shareholders do not receive dividends, if any, from shares of ARKK. The strategy works best for investors willing to hold shares the entire outcome period. Outcomes will differ for those buying/selling mid-period.
Full ARKD Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.